University of Texas Southwestern Medical Center (UT Southwestern)

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial (2023) McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JF, Marx N, Mulvagh SL, et al. Journal article International Consensus on Standardized Clinic Blood Pressure Measurement – A Call to Action (2023) Cheung AK, Whelton PK, Muntner P, Schutte AE, Moran AE, Williams B, Sarafidis P, et al. Journal article Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy (2023) Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, et al. Journal article GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus (2023) Levy C, Kendrick S, Bowlus CL, Tanaka A, Jones D, Kremer A, Mayo MJ, et al. Journal article Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma (2023) Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, Cammarota A, et al. Journal article A tribute to Prof. Ondrej Hes, MD, PhD (1968-2022) (2022) Alaghehbandan R, Agaimy A, Ali L, Alvarado-Cabrero I, Amin MB, Boudova L, Calio A, et al. Journal article CAD-RADS™ 2.0 - 2022 Coronary Artery Disease - Reporting and Data System.: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR) and the North America Society of Cardiovascular Imaging (NASCI) (2022) Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, Budoff M, et al. Journal article, Original article CAD-RADS(TM) 2.0-2022 Coronary Artery Disease-Reporting and Data System (2022) Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, Budoff M, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel (2022) Burdon KP, Graham P, Hadler J, Hulleman JD, Pasutto F, Boese EA, Craig JE, et al. Journal article